We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Video

Breast Cancer Treatment – Prof. Andrew Tutt on the OlympiA Trial

June 14 2021 
| Taken from The Institute of Cancer Research, YouTube
Rectangle Image
Video

Breast Cancer Treatment – Prof. Andrew Tutt on the OlympiA Trial

June 14 2021 
| Taken from The Institute of Cancer Research, YouTube
Credit: The Institute of Cancer Research, YouTube
The results of the OlympiA clinical trial, involving ICR researchers, shows giving the drug olaparib for one year to breast cancer patients with inherited BRCA mutations, after they have completed initial treatment, reduced the chance of their breast cancer returning.

Professor Andrew Tutt, Head of Breast Cancer Research at the ICR, explains more.

Advertisement
Chosen for you
Advertisement
Advertisement